Omnicell, Inc. (NASDAQ:OMCL) issued its quarterly earnings data on Thursday, October 26th. The company reported $0.42 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.42, Bloomberg Earnings reports. Omnicell had a negative return on equity of 0.79% and a negative net margin of 0.51%. The business had revenue of $186.78 million for the quarter, compared to the consensus estimate of $192.45 million. During the same period in the prior year, the business earned $0.40 earnings per share. The business’s revenue was up 5.7% on a year-over-year basis. Omnicell updated its Q4 guidance to $0.49-0.55 EPS.
Shares of Omnicell (OMCL) opened at $46.40 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.53 and a debt-to-equity ratio of 0.38. Omnicell has a 12 month low of $31.50 and a 12 month high of $55.40.
ILLEGAL ACTIVITY WARNING: “Omnicell, Inc. (OMCL) Issues Quarterly Earnings Results” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://stocknewstimes.com/2017/11/11/omnicell-inc-omcl-releases-earnings-results-meets-estimates.html.
OMCL has been the topic of several recent analyst reports. Zacks Investment Research downgraded Omnicell from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 1st. Craig Hallum restated a “buy” rating and issued a $62.00 price objective (up from $52.00) on shares of Omnicell in a report on Monday, October 30th. Cantor Fitzgerald restated a “buy” rating and issued a $47.00 price objective on shares of Omnicell in a report on Tuesday, July 25th. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $55.00 price objective on shares of Omnicell in a report on Thursday, October 19th. Finally, Dougherty & Co raised their price objective on Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company. Omnicell has a consensus rating of “Buy” and an average price target of $54.86.
In other news, VP Jorge R. Taborga sold 6,295 shares of Omnicell stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $48.69, for a total value of $306,503.55. Following the completion of the transaction, the vice president now owns 50,013 shares in the company, valued at approximately $2,435,132.97. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Robin Gene Seim sold 15,109 shares of Omnicell stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $50.86, for a total value of $768,443.74. Following the completion of the transaction, the executive vice president now owns 58,144 shares of the company’s stock, valued at approximately $2,957,203.84. The disclosure for this sale can be found here. In the last quarter, insiders sold 62,741 shares of company stock valued at $3,139,399. Insiders own 3.77% of the company’s stock.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.